Total Funding
25
36
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
239061
MetaStat develops diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
Douglas A. Hamilton: President and Chief Executive Officer
About the Company
MetaStat is focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis, a cancer that spreads from a primary tumor through the bloodstream to other areas of the body. The company also develops a prognostic diagnostic program which is focused on
developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
